ed@mygoodprofile.com

Home/Ed olimpio

About Ed olimpio

This author has not yet filled in any details.
So far Ed olimpio has created 34 blog entries.

Improved Pharma announces new publication on amorphous dispersions

A recent collaboration with our colleagues further advances the field of X-ray pair distribution function analysis applied to the analysis of amorphous solid dispersions. In this paper, we present the results of different polymer:flubendazole drug dispersions exposed to aging conditions. We discovered that if the polymer has ion-base interactions with the drug, the resulting Read more

Improved Pharma announces new publication on amorphous dispersions2021-04-09T18:41:26+00:00

Control of Nitrosamine Impurities in Human Drugs

In February 2021, the FDA issued a guidance aimed at preventing unacceptable levels of nitrosamine impurities in pharmaceutical products.  This guidance required a risk assessment to be completed by March 31, 2021.  This is because nitrosamines are genotoxic and are classified as possible or probable carcinogens. The guidance also described conditions under which nitrosamines can Read more

Control of Nitrosamine Impurities in Human Drugs2021-03-12T22:14:19+00:00

Recent research on bedaquiline selected for the November cover of Acta Crystallographic

Improved Pharma is pleased to announce the open-source publication of research into finding new salts of bedaquiline, an important drug for the treatment of tuberculosis. The drug is currently marketed in the US as the fumarate salt. Our team discovered several new salts, and the crystal structures of two benzoate salts are described in this Read more

Recent research on bedaquiline selected for the November cover of Acta Crystallographic2020-12-14T13:52:51+00:00

Improved Pharma presenting at AAPS 2020 PHARMSCI 360 with Rapid Fire Presentation and Poster

WEST LAFAYETTE, IND. (PRWEB) OCTOBER 26, 2020 Interact with us via poster number 924440 and the Advances and Innovation in Formulation Development Rapid Fire session. On Wednesday October 28th, Dr. Pamela Smith, COO of Improved Pharma, will present “Synchrotron-Based Formulation Development” in the Rapid Fire: Formulation and Quality – Chemical session. Those registered for the meeting Read more

Improved Pharma presenting at AAPS 2020 PHARMSCI 360 with Rapid Fire Presentation and Poster2020-10-26T17:34:00+00:00

Published book chapter on Solid-State Characterization

Improved Pharma COO Pamela Smith is co-author of a chapter in the latest edition of Specification of Drug Substances and Products: Development and Validation of Analytical Methods. The chapter, Solid-State Characterization – Method Development and Validation, focuses on the key issues that must be addressed when developing solid-state methods. Method development and validation for pharmaceuticals is Read more

Published book chapter on Solid-State Characterization2020-10-21T15:04:46+00:00

Excipient Effects on Drug Product Performance

Traditionally, excipients utilized for the development of pharmaceutically-marketed drug products have been considered largely inert. Excipients are added to formulations for a variety of reasons that may include assisting processability of the drug product formulation, controlling the disintegration rate to facilitate regional dissolution along the gastrointestinal tract (GIT), bulking up the dosage form to enable Read more

Excipient Effects on Drug Product Performance2020-09-21T19:19:30+00:00

Improved Pharma Announces New UV-Vis Capabilities and Expanded Dissolution Services

WEST LAFAYETTE, IND. (PRWEB) SEPTEMBER 15, 2020 Improved Pharma has expanded their offerings by acquiring S. I. Photonics’ top-of-the-line spectrophotometer, model 440. This model has a high sensitivity, low noise CCD detector that enables the collection of a full spectrum within a second. The power of this instrument is enhanced by the number of accessories and Read more

Improved Pharma Announces New UV-Vis Capabilities and Expanded Dissolution Services2020-09-16T19:51:23+00:00

Improved Pharma Announces New Collaborations Enabling Expansion Of Services

WEST LAFAYETTE, IND. (PRWEB) JULY 20, 2020 Improved Pharma is pleased to announce new collaborations with Westport Pharmaceutical Consulting, LLC (dba WPC, LLC) and Ravine Pharmaceuticals LLC enabling expansion of expertise and service offerings to the pharmaceutical industry in support of drug substance and drug product development. These additions bring a vast amount of relevant industrial Read more

Improved Pharma Announces New Collaborations Enabling Expansion Of Services2020-07-21T14:03:08+00:00

Learn about Improved Pharma’s approach to polymorph and salt screening

Polymorph screens and salt screens are important components for drug development. The goal of polymorph screening is to try to find all possible crystal forms by small-scale crystallization and to select a stable form that can be manufactured and formulated into a dosage form. Salt screens are commonly used to alter the physicochemical properties of Read more

Learn about Improved Pharma’s approach to polymorph and salt screening2020-07-15T20:52:18+00:00

Improved Pharma Introduces Synchrotron-Based Fast to IND (S-fIND) Development Services

Accelerated development is a complex and difficult task. S-fIND (Synchrotron-based fast to IND) is a strategy to speed development of the most difficult cases using powerful X-ray methods only available at a Synchrotron X-ray source.  S-fIND integrates powerful methods with practical pharmaceutical development approaches and excellent people in a package that accelerates development. Accelerated development services Read more

Improved Pharma Introduces Synchrotron-Based Fast to IND (S-fIND) Development Services2020-06-04T00:32:02+00:00
Go to Top